The potential of live attenuated vaccines against Cutaneous Leishmaniasis
Cutaneous Leishmaniasis is a serious public health problem, typically affecting poor populations with limited access to health care. Control is largely dependent on chemotherapies that are inefficient, costly and challenging to deliver. Vaccination is an attractive and feasible alternative because l...
Gespeichert in:
| Veröffentlicht in: | Experimental parasitology 2020-03, Vol.210, p.107849-107849, Article 107849 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 107849 |
|---|---|
| container_issue | |
| container_start_page | 107849 |
| container_title | Experimental parasitology |
| container_volume | 210 |
| creator | Zabala-Peñafiel, A. Todd, D. Daneshvar, H. Burchmore, R. |
| description | Cutaneous Leishmaniasis is a serious public health problem, typically affecting poor populations with limited access to health care. Control is largely dependent on chemotherapies that are inefficient, costly and challenging to deliver. Vaccination is an attractive and feasible alternative because long-term protection is typical in patients who recover from the disease. No human vaccine is yet approved for use, but several candidates are at various stages of testing. Live attenuated parasites, which stimulate long-term immune protection, have potential as effective vaccines, and their challenges relating to safety, formulation and delivery can be overcome. Here we review current data on the potential of live attenuated Leishmania vaccines and discuss possible routes to regulatory approval.
•Leishmaniasis is a vaccinable disease.•Live attenuated Leishmania parasites can stimulate long term protection from disease.•We discuss challenges and possible routes to approval of live attenuated Leishmania vaccines. |
| doi_str_mv | 10.1016/j.exppara.2020.107849 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2352639907</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014489419304448</els_id><sourcerecordid>2352639907</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-2ba6673f3fabdcb27d8582b51fb391f11b28f52d5a6f9491b346daa6c7795e3d3</originalsourceid><addsrcrecordid>eNqFkElPwzAQhS0EomX5CaAcuaR4y-ITQhWbVIkLnK2JPaau0iTETgX_nlQpXDmN9PTevJmPkCtGF4yy_HazwK-ugx4WnPK9VpRSHZE5o4qmXEp1TOaUMpnKUskZOQthQyktGZenZCbGTFEqPicvb2tMujZiEz3USeuS2u8wgTgqA0S0yQ6M8Q2GBD7ANyEmyyFCg-0QkhX6sN5C4yH4cEFOHNQBLw_znLw_Prwtn9PV69PL8n6VGilYTHkFeV4IJxxU1lS8sGVW8ipjrhKKOcYqXrqM2wxyp6RilZC5BchNUagMhRXn5Gba2_Xt54Ah6q0PBut6OkpzkfFcKEWL0ZpNVtO3IfTodNf7LfTfmlG9p6g3-kBR7ynqieKYuz5UDNUW7V_qF9touJsMOD6689jrYDw2Bq3v0URtW_9PxQ_FHYaM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2352639907</pqid></control><display><type>article</type><title>The potential of live attenuated vaccines against Cutaneous Leishmaniasis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Zabala-Peñafiel, A. ; Todd, D. ; Daneshvar, H. ; Burchmore, R.</creator><creatorcontrib>Zabala-Peñafiel, A. ; Todd, D. ; Daneshvar, H. ; Burchmore, R.</creatorcontrib><description>Cutaneous Leishmaniasis is a serious public health problem, typically affecting poor populations with limited access to health care. Control is largely dependent on chemotherapies that are inefficient, costly and challenging to deliver. Vaccination is an attractive and feasible alternative because long-term protection is typical in patients who recover from the disease. No human vaccine is yet approved for use, but several candidates are at various stages of testing. Live attenuated parasites, which stimulate long-term immune protection, have potential as effective vaccines, and their challenges relating to safety, formulation and delivery can be overcome. Here we review current data on the potential of live attenuated Leishmania vaccines and discuss possible routes to regulatory approval.
•Leishmaniasis is a vaccinable disease.•Live attenuated Leishmania parasites can stimulate long term protection from disease.•We discuss challenges and possible routes to approval of live attenuated Leishmania vaccines.</description><identifier>ISSN: 0014-4894</identifier><identifier>EISSN: 1090-2449</identifier><identifier>DOI: 10.1016/j.exppara.2020.107849</identifier><identifier>PMID: 32027892</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Cutaneous Leishmaniasis ; Disease Models, Animal ; Humans ; Leishmania ; Leishmania - immunology ; Leishmaniasis, Cutaneous - prevention & control ; Leishmanization ; Live attenuated parasites ; Protozoan Vaccines ; Vaccines ; Vaccines, Attenuated</subject><ispartof>Experimental parasitology, 2020-03, Vol.210, p.107849-107849, Article 107849</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-2ba6673f3fabdcb27d8582b51fb391f11b28f52d5a6f9491b346daa6c7795e3d3</citedby><cites>FETCH-LOGICAL-c431t-2ba6673f3fabdcb27d8582b51fb391f11b28f52d5a6f9491b346daa6c7795e3d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.exppara.2020.107849$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32027892$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zabala-Peñafiel, A.</creatorcontrib><creatorcontrib>Todd, D.</creatorcontrib><creatorcontrib>Daneshvar, H.</creatorcontrib><creatorcontrib>Burchmore, R.</creatorcontrib><title>The potential of live attenuated vaccines against Cutaneous Leishmaniasis</title><title>Experimental parasitology</title><addtitle>Exp Parasitol</addtitle><description>Cutaneous Leishmaniasis is a serious public health problem, typically affecting poor populations with limited access to health care. Control is largely dependent on chemotherapies that are inefficient, costly and challenging to deliver. Vaccination is an attractive and feasible alternative because long-term protection is typical in patients who recover from the disease. No human vaccine is yet approved for use, but several candidates are at various stages of testing. Live attenuated parasites, which stimulate long-term immune protection, have potential as effective vaccines, and their challenges relating to safety, formulation and delivery can be overcome. Here we review current data on the potential of live attenuated Leishmania vaccines and discuss possible routes to regulatory approval.
•Leishmaniasis is a vaccinable disease.•Live attenuated Leishmania parasites can stimulate long term protection from disease.•We discuss challenges and possible routes to approval of live attenuated Leishmania vaccines.</description><subject>Animals</subject><subject>Cutaneous Leishmaniasis</subject><subject>Disease Models, Animal</subject><subject>Humans</subject><subject>Leishmania</subject><subject>Leishmania - immunology</subject><subject>Leishmaniasis, Cutaneous - prevention & control</subject><subject>Leishmanization</subject><subject>Live attenuated parasites</subject><subject>Protozoan Vaccines</subject><subject>Vaccines</subject><subject>Vaccines, Attenuated</subject><issn>0014-4894</issn><issn>1090-2449</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkElPwzAQhS0EomX5CaAcuaR4y-ITQhWbVIkLnK2JPaau0iTETgX_nlQpXDmN9PTevJmPkCtGF4yy_HazwK-ugx4WnPK9VpRSHZE5o4qmXEp1TOaUMpnKUskZOQthQyktGZenZCbGTFEqPicvb2tMujZiEz3USeuS2u8wgTgqA0S0yQ6M8Q2GBD7ANyEmyyFCg-0QkhX6sN5C4yH4cEFOHNQBLw_znLw_Prwtn9PV69PL8n6VGilYTHkFeV4IJxxU1lS8sGVW8ipjrhKKOcYqXrqM2wxyp6RilZC5BchNUagMhRXn5Gba2_Xt54Ah6q0PBut6OkpzkfFcKEWL0ZpNVtO3IfTodNf7LfTfmlG9p6g3-kBR7ynqieKYuz5UDNUW7V_qF9touJsMOD6689jrYDw2Bq3v0URtW_9PxQ_FHYaM</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Zabala-Peñafiel, A.</creator><creator>Todd, D.</creator><creator>Daneshvar, H.</creator><creator>Burchmore, R.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202003</creationdate><title>The potential of live attenuated vaccines against Cutaneous Leishmaniasis</title><author>Zabala-Peñafiel, A. ; Todd, D. ; Daneshvar, H. ; Burchmore, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-2ba6673f3fabdcb27d8582b51fb391f11b28f52d5a6f9491b346daa6c7795e3d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Cutaneous Leishmaniasis</topic><topic>Disease Models, Animal</topic><topic>Humans</topic><topic>Leishmania</topic><topic>Leishmania - immunology</topic><topic>Leishmaniasis, Cutaneous - prevention & control</topic><topic>Leishmanization</topic><topic>Live attenuated parasites</topic><topic>Protozoan Vaccines</topic><topic>Vaccines</topic><topic>Vaccines, Attenuated</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zabala-Peñafiel, A.</creatorcontrib><creatorcontrib>Todd, D.</creatorcontrib><creatorcontrib>Daneshvar, H.</creatorcontrib><creatorcontrib>Burchmore, R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental parasitology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zabala-Peñafiel, A.</au><au>Todd, D.</au><au>Daneshvar, H.</au><au>Burchmore, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The potential of live attenuated vaccines against Cutaneous Leishmaniasis</atitle><jtitle>Experimental parasitology</jtitle><addtitle>Exp Parasitol</addtitle><date>2020-03</date><risdate>2020</risdate><volume>210</volume><spage>107849</spage><epage>107849</epage><pages>107849-107849</pages><artnum>107849</artnum><issn>0014-4894</issn><eissn>1090-2449</eissn><abstract>Cutaneous Leishmaniasis is a serious public health problem, typically affecting poor populations with limited access to health care. Control is largely dependent on chemotherapies that are inefficient, costly and challenging to deliver. Vaccination is an attractive and feasible alternative because long-term protection is typical in patients who recover from the disease. No human vaccine is yet approved for use, but several candidates are at various stages of testing. Live attenuated parasites, which stimulate long-term immune protection, have potential as effective vaccines, and their challenges relating to safety, formulation and delivery can be overcome. Here we review current data on the potential of live attenuated Leishmania vaccines and discuss possible routes to regulatory approval.
•Leishmaniasis is a vaccinable disease.•Live attenuated Leishmania parasites can stimulate long term protection from disease.•We discuss challenges and possible routes to approval of live attenuated Leishmania vaccines.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32027892</pmid><doi>10.1016/j.exppara.2020.107849</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-4894 |
| ispartof | Experimental parasitology, 2020-03, Vol.210, p.107849-107849, Article 107849 |
| issn | 0014-4894 1090-2449 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2352639907 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Cutaneous Leishmaniasis Disease Models, Animal Humans Leishmania Leishmania - immunology Leishmaniasis, Cutaneous - prevention & control Leishmanization Live attenuated parasites Protozoan Vaccines Vaccines Vaccines, Attenuated |
| title | The potential of live attenuated vaccines against Cutaneous Leishmaniasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T16%3A37%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20potential%20of%20live%20attenuated%20vaccines%20against%20Cutaneous%20Leishmaniasis&rft.jtitle=Experimental%20parasitology&rft.au=Zabala-Pe%C3%B1afiel,%20A.&rft.date=2020-03&rft.volume=210&rft.spage=107849&rft.epage=107849&rft.pages=107849-107849&rft.artnum=107849&rft.issn=0014-4894&rft.eissn=1090-2449&rft_id=info:doi/10.1016/j.exppara.2020.107849&rft_dat=%3Cproquest_cross%3E2352639907%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2352639907&rft_id=info:pmid/32027892&rft_els_id=S0014489419304448&rfr_iscdi=true |